title: Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity.
abstract: The natural history of lung hyperinflation in patients with airway obstruction is unknown. In particular, little information exists about the extent of air trapping and its reversibility to bronchodilator therapy in those with mild airway obstruction. We completed a retrospective analysis of data from individuals with airway obstruction who attended our pulmonary function laboratory and had plethysmographic lung volume measurements pre- and post-bronchodilator (salbutamol). COPD was likely the predominant diagnosis but patients with asthma may have been included. We studied 2,265 subjects (61% male), age 65 ± 9 years (mean ± SD) with a post-bronchodilator FEV(1)/FVC <0.70. We examined relationships between indices of airway obstruction and lung hyperinflation, and measured responses to bronchodilation across subgroups stratified by GOLD criteria. In GOLD stage I, vital capacity (VC) and inspiratory capacity (IC) were in the normal range; pre-bronchodilator residual volume (RV), functional residual capacity (FRC) and specific airway resistance were increased to 135%, 119% and 250% of predicted, respectively. For the group as a whole, RV and FRC increased exponentially as FEV(1) decreased, while VC and IC decreased linearly. Regardless of baseline FEV(1), the most consistent improvement following bronchodilation was RV reduction, in terms of magnitude and responder rate. In conclusion, increases (above normal) in airway resistance and plethysmographic lung volumes were found in those with only minor airway obstruction. Indices of lung hyperinflation increased exponentially as airway obstruction worsened. Those with the greatest resting lung hyperinflation showed the largest bronchodilator-induced volume deflation effects. Reduced air trapping was the predominant response to acute bronchodilation across severity subgroups.
authors.affiliation: Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada. adeesomc@mail.med.cmu.ac.th
authors.forename: Athavudh
authors.initials: A
authors.lastname: Deesomchok
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Webb
authors.forename: Lutz
authors.initials: L
authors.lastname: Forkert
authors.forename: Yuk-Miu
authors.initials: YM
authors.lastname: Lam
authors.forename: Dror
authors.initials: D
authors.lastname: Ofir
authors.forename: Dennis
authors.initials: D
authors.lastname: Jensen
authors.forename: Denis E
authors.initials: DE
authors.lastname: O'Donnell
mesh_terms: D000368:Aged; D000402:Airway Obstruction / Q000188:drug therapy* / Q000503:physiopathology; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D010991:Plethysmography; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000503:physiopathology*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol